MetaVia (MTVA) Operating Income (2015 - 2026)
MetaVia's (MTVA) quarterly Operating Income came in at -$2.0 million in Q4 2025, up 63.37% YoY from -$1.3 million in Q4 2024, and up 41.12% on a QoQ basis from -$3.5 million in Q3 2025.
MetaVia (MTVA) Operating Income (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 9 years of Operating Income data on file, last reported at -$2.0 million in Q4 2025.
- Quarterly Operating Income rose 63.37% year-over-year to -$2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.7 million (up 52.42% YoY) and the FY2025 annual result came in at -$13.7 million, up 52.42% from the prior year.
- Operating Income grew to -$2.0 million in Q4 2025, from -$3.5 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.0 million in Q4 2025 to a low of -$10.4 million in Q4 2022.
- A 4-year average of -$5.1 million and a median of -$4.1 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income slumped 173.06% — and 2025, when it surged 63.37%.
- Tracing MTVA's Operating Income over 4 years: stood at -$10.4 million in 2022, then jumped by 75.84% to -$2.5 million in 2023, then slumped by 121.63% to -$5.6 million in 2024, then surged by 63.37% to -$2.0 million in 2025.
- The last three Operating Income figures came in at -$2.0 million (Q4 2025), -$3.5 million (Q3 2025), and -$4.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | -5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.39 Mn |
| Dec 31, 2025 | -2.05 Mn |
| Sep 30, 2025 | -3.48 Mn |
| Jun 30, 2025 | -4.30 Mn |
| Mar 31, 2025 | -3.89 Mn |
| Dec 31, 2024 | -5.59 Mn |
| Sep 30, 2024 | -6.26 Mn |
| Jun 30, 2024 | -10.08 Mn |
| Mar 31, 2024 | -6.88 Mn |
| Mar 31, 2023 | -2.52 Mn |
| Dec 31, 2022 | -10.43 Mn |
| Sep 30, 2022 | -3.10 Mn |
| Jun 30, 2022 | -3.22 Mn |
| Sep 30, 2019 | -2.32 Mn |
| Jun 30, 2019 | -2.35 Mn |
| Mar 31, 2019 | -2.80 Mn |
| Dec 31, 2018 | -3.30 Mn |
| Sep 30, 2018 | -5.91 Mn |
| Jun 30, 2018 | -6.53 Mn |
| Mar 31, 2018 | -7.06 Mn |